Phase III trial of orally administered ibandronic acid, compared with intravenously administered ibandronic acid (Bonviva IV Injection), in patients with osteoporosis in Japan.

Trial Profile

Phase III trial of orally administered ibandronic acid, compared with intravenously administered ibandronic acid (Bonviva IV Injection), in patients with osteoporosis in Japan.

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Sep 2016

At a glance

  • Drugs Ibandronic acid (Primary) ; Ibandronic acid
  • Indications Osteoporosis
  • Focus Registrational; Therapeutic Use
  • Acronyms MOVEST
  • Sponsors Chugai Pharmaceutical; Taisho Pharmaceutical
  • Most Recent Events

    • 17 Apr 2016 Results of sub-group analysis (n=422) presented at the 2016 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases
    • 22 Jan 2016 According to Chugai Pharmaceuticals media release, company has filed a new drug application to the MHLW.
    • 22 Jan 2016 Results published in Chugai Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top